Table 2.

Linear Regression Analysis Between Baseline Variables and CD4 T-Cell Counts or CD4 T-Cell Nadir in Viremic Progressors^a (n = 337)

Variable	Bivariate	Multivariateb	Multivariatec
	P Value; β (95% CI)d
CD4 T-cell levels
Sex, male	.531; –19.1 (–79.0 to 40.8)
Age, y	<.001; –5.3 (–7.7 to –2.9)	<.001; –4.3 (–6.8 to –1.9)	.01; –3.9 (–6.3 to –1.5)
Time of diagnosis, y	.029; –9.0 (–17.1 to –0.9)	.082; –6.9 (–14.6 to –.9)	.01; –10.3 (–18.1 to –2.5)
Log10 VL, HIV-RNA copies/mL	<.001; –60.7 (–86.0 to –35.3)	<.001; –53.2 (–78.3 to –28.1)	<.001; –48.2 (–73.2 to –23.3)
sj/β-TREC ratio	.092; 0.4 (–.1 to .9)	.565; 0.14 (–.34 to .62)
sj/β-TREC ratio <10e	<.001; –114.7 (–168.2 to –61.2)		.002; –81.9 (–134.5 to –29.2)
CD4 nadir
Sex, male	.085; –29.1 (–62.3 to 4.0)	.011; –42.4 (–74.9 to –9.8)	.011; –41.5 (–73.5 to –9.4)
Age, y	<.001; –2.8 (–4.1 to –1.4)	.001; –2.3 (–3.7 to –.9)	.001; –2.2 (–3.6 to –.9)
Time since diagnosis, y	.400; –1.9 (–6.4 to 2.6)
Log10 VL, HIV-RNA copies/mL	<.001; –25.9 (–40.2 to –11.6)	.001; –23.6 (–37.8 to –9.5)	.003; –21.7 (–35.9 to –7.6)
sj/β-TREC ratio	.007; 0.4 (.1–.7)	.035; 0.3 (.02–.6)
sj/β-TREC ratio <10e	<.001; –61.9 (–91.7 to –32.2)		.001; –48.9 (–19.2 to –78.5)

Dependent variables are shown underlined. Significant covariates are shown in bold. Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; sj/β-TREC, signal-joint/DβJβ T-cell rearrangement excision circle; VL, viral load.

^aNaive patients for antiretroviral treatment in the progressor cohort.

^bAge, time of diagnosis, log₁₀ VL, and sj/β-TREC ratio were used as covariates.

^cAge, time of diagnosis, log₁₀ VL, and sj/β-TREC ratio <10 were used as covariates.

^dRegression coefficient and 95% confidence interval.

^eThymic failure threshold.